ORGANIZATION

• BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
  March 25, 2026

• Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
  March 24, 2026

• FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
  March 24, 2026

• FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
  March 23, 2026

• JPMA Names Shionogi’s Go Takahashi as Managing Director
  March 23, 2026

• JPMA Seeks Japan Version of EHDS to Unlock Life-Course Health Data
  March 23, 2026

• EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
  March 2, 2026

• Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
  February 24, 2026

• JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
  February 20, 2026

• Pharma Group Looks to Growth Strategy under Takaichi after Election Win
  February 10, 2026

• Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
  February 9, 2026

• Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
  February 6, 2026

• FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
  February 3, 2026

• AMDD to Continue Policy Advocacy to Address Device Lag and Loss: Chair
  January 28, 2026

• Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says
  January 23, 2026

• Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
  January 21, 2026

• OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
  January 20, 2026

• JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
  January 20, 2026

• Pharma FTC Clarifies “Simple Beverages” under New Food Rules
  January 14, 2026

• EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
  January 9, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »